Wilson Sonsini Advises Assort Health on $120 Million Series C

"Wilson Sonsini Goodrich & Rosati advised Assort Health on a $120 million Series C led by Menlo Ventures at a $1.2 billion valuation. Participating investors included Lightspeed, Felicis, First Round, Chemistry, Joe Montana, Tau Ventures, and Quiet Capital. The financing brings Assort's total funding to over $222 million for its AI patient-journey platform."

Wilson Sonsini Goodrich & Rosati advised Assort Health on its $120 million Series C financing. The Series C was led by Menlo Ventures at a $1.2 billion valuation. Participating investors included Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures, and Quiet Capital. With this round, Assort has raised more than $222 million to date. Assort Health operates an AI agents platform for the patient journey. What began as the first voice AI agent to schedule specialty appointments has expanded into a platform that covers scheduling, intake forms, referrals, document processing, medication refills, real-time eligibility, lab requests, and payments. That expansion has been supported by more than 190 million patient interactions, 62,000 care protocols, and 1.6 million decision pathways, creating the largest proprietary specialty dataset in healthcare. Wilson Sonsini Goodrich & Rosati represented Assort Health with a team composed by: Lang Liu, Alex Youssef, Madisyn Klein, and Nara Jo.

Menu

Wilson Sonsini Advises Assort Health on $120 Million Series C

Read the full story

Menu

Wilson Sonsini Advises Assort Health on $120 Million Series C

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads